Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time
April 30 2024 - 8:30AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
upgrades to its Platinum® Analysis Software to reduce processing
time and increase output and precision of Next-Generation Protein
Sequencing™ (NGPS) data from the Platinum® instrument.
“A core component of our Platinum Analysis Software is a
database of predicted kinetic signatures that today, contains
nearly two million parameters and is generated by our proprietary
kinetic model,” said John Vieceli, Senior Vice President of Product
Development at Quantum-Si. “Leveraging artificial intelligence and
generated sequencing data, we are able to continuously train our
model and improve the accuracy of the database, resulting in higher
data output and precision.”
Innovations in this release of the Platinum Analysis Software
will provide customers with an average of:
- 55% increase in the number of peptide alignments of protein
samples
- 9% increase in the precision of identifying unknown proteins
present in a given sample
- 70% reduction in primary analysis time from 85 minutes to 25
minutes
“Innovations to our Platinum Analysis Software represent a
significant opportunity to unlock even deeper insights from our
Next-Generation Protein Sequencing technology further building upon
the improvements we continue to deliver to the sequencing
chemistry,” said Jeff Hawkins, President and CEO of Quantum-Si.
“The Platinum Analysis Software enhancements we are launching today
represent another significant leap forward in our commitment to
continuously provide customers with innovations that deliver
tangible value to their proteomics research.”
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at quantum-si.com or
follow us on LinkedIn or X.
Forward Looking Statements This press release includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. The actual results of the Company
may differ from its expectations, estimates, and projections and,
consequently, you should not rely on these forward-looking
statements as predictions of future events. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate,"
"intend," "plan," "may," "will," "could," "should," "believes,"
"predicts," "potential," "continue," and similar expressions (or
the negative versions of such words or expressions) are intended to
identify such forward-looking statements. These forward-looking
statements include, without limitation, the Company's expectations
with respect to future performance and development and
commercialization of products and services. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from those discussed
in the forward-looking statements. Most of these factors are
outside the Company's control and are difficult to predict. Factors
that may cause such differences include, but are not limited to:
the inability to maintain the listing of the Company's Class A
common stock on The Nasdaq Stock Market; the ability of the Company
to grow and manage growth profitably and retain its key employees;
the Company’s ongoing leadership transitions; changes in applicable
laws or regulations; the ability of the Company to raise financing
in the future; the success, cost and timing of the Company's
product development and commercialization activities; the
commercialization and adoption of the Company’s existing products
and the success of any product the Company may offer in the future;
the potential attributes and benefits of the Company’s
commercialized Platinum™ protein sequencing instrument and kits and
the Company’s other products once commercialized; the Company's
ability to obtain and maintain regulatory approval for its
products, and any related restrictions and limitations of any
approved product; the Company's ability to identify, in-license or
acquire additional technology; the Company's ability to maintain
its existing lease, license, manufacture and supply agreements; the
Company's ability to compete with other companies currently
marketing or engaged in the development or commercialization of
products and services that serve customers engaged in proteomic
analysis, many of which have greater financial and marketing
resources than the Company; the size and growth potential of the
markets for the Company's products and services, and its ability to
serve those markets once commercialized, either alone or in
partnership with others; the Company's estimates regarding future
expenses, future revenue, capital requirements and needs for
additional financing; the Company's financial performance; and
other risks and uncertainties described under "Risk Factors" in the
Company’s most recent Annual Report on Form 10-K, and in the
Company's other filings with the SEC. The Company cautions that the
foregoing list of factors is not exclusive. The Company cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430849848/en/
Investor Contact Jeff Keyes, Chief Financial Officer
ir@quantum-si.com
Media Contact Katherine Atkinson, SVP, Commercial
Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Nov 2023 to Nov 2024